n/a
Article Publish Status: FREE
Abstract Title:

AltilixSupplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study.

Abstract Source:

Nutrients. 2019 Oct 25 ;11(11). Epub 2019 Oct 25. PMID: 31731527

Abstract Author(s):

Giuseppa Castellino, Dragana Nikolic, Antonio Magán-Fernández, Giuseppe Antonio Malfa, Roberta Chianetta, Angelo M Patti, Antonella Amato, Giuseppe Montalto, Peter P Toth, Maciej Banach, Arrigo F G Cicero, Manfredi Rizzo

Article Affiliation:

Giuseppa Castellino

Abstract:

The objective was to evaluate the effects of 6 months of supplementation with Altilix, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix(26 men and 24 women, mean age 63± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilixsupplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01);<0.001), waist circumference (-2.76% (95% CI -4.55, -0.96);= 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67);<0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27);<0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12);<0.001), and carotid intima-media thickness (-39.48% (95% CI -47.98, -30.97);<0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilixsupplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilixsupplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects.

Print Options


Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2020 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.